A board-certified neurologist and pharmacist, Friedrich is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal anti‑VEGF and other ophthalmic therapies at Bayer Pharma, including indications such as diabetic macular edema, diabetic retinopathy, and retinal vein occlusions. Friedrich previously worked on rare ophthalmic diseases at ProQR Therapeutics and as Senior Vice President of Clinical Development for an intravitreal cell therapy for Retinitis Pigmentosa at jCyte.